These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
405 related articles for article (PubMed ID: 26231497)
1. The cardiac safety of aripiprazole treatment in patients at high risk for torsade: a systematic review with a meta-analytic approach. Polcwiartek C; Sneider B; Graff C; Taylor D; Meyer J; Kanters JK; Nielsen J Psychopharmacology (Berl); 2015 Sep; 232(18):3297-308. PubMed ID: 26231497 [TBL] [Abstract][Full Text] [Related]
2. Antipsychotic-related QTc prolongation, torsade de pointes and sudden death. Haddad PM; Anderson IM Drugs; 2002; 62(11):1649-71. PubMed ID: 12109926 [TBL] [Abstract][Full Text] [Related]
4. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Glassman AH; Bigger JT Am J Psychiatry; 2001 Nov; 158(11):1774-82. PubMed ID: 11691681 [TBL] [Abstract][Full Text] [Related]
5. QTc interval prolongation and torsade de pointes associated with second-generation antipsychotics and antidepressants: a comprehensive review. Hasnain M; Vieweg WV CNS Drugs; 2014 Oct; 28(10):887-920. PubMed ID: 25168784 [TBL] [Abstract][Full Text] [Related]
6. Assessing QT interval prolongation and its associated risks with antipsychotics. Nielsen J; Graff C; Kanters JK; Toft E; Taylor D; Meyer JM CNS Drugs; 2011 Jun; 25(6):473-90. PubMed ID: 21649448 [TBL] [Abstract][Full Text] [Related]
7. Proarrhythmic risk with antipsychotic and antidepressant drugs: implications in the elderly. Vieweg WV; Wood MA; Fernandez A; Beatty-Brooks M; Hasnain M; Pandurangi AK Drugs Aging; 2009; 26(12):997-1012. PubMed ID: 19929028 [TBL] [Abstract][Full Text] [Related]
9. [Minimizing the risks associated with QTc prolongation in people with schizophrenia. A consensus statement by the Cardiac Safety in Schizophrenia Group]. Ames D; Camm J; Cook P; Falkai P; Gury C; Hurley R; Johnson G; Piepho R; Vieweg V; Encephale; 2002; 28(6 Pt 1):552-62. PubMed ID: 12506268 [TBL] [Abstract][Full Text] [Related]
10. Risperidone, QTc interval prolongation, and torsade de pointes: a systematic review of case reports. Vieweg WV; Hasnain M; Hancox JC; Baranchuk A; Digby GC; Kogut C; Crouse EL; Koneru JN; Deshmukh A; Pandurangi AK Psychopharmacology (Berl); 2013 Aug; 228(4):515-24. PubMed ID: 23812796 [TBL] [Abstract][Full Text] [Related]
11. Obstructive Sleep Apnea in Patients with Congenital Long QT Syndrome: Implications for Increased Risk of Sudden Cardiac Death. Shamsuzzaman AS; Somers VK; Knilans TK; Ackerman MJ; Wang Y; Amin RS Sleep; 2015 Jul; 38(7):1113-9. PubMed ID: 26118557 [TBL] [Abstract][Full Text] [Related]
12. Risk management of QTc-prolongation in patients receiving haloperidol: an epidemiological study in a University hospital in Belgium. Vandael E; Vandenberk B; Vandenberghe J; Spriet I; Willems R; Foulon V Int J Clin Pharm; 2016 Apr; 38(2):310-20. PubMed ID: 26749342 [TBL] [Abstract][Full Text] [Related]
13. Ziprasidone in the management of schizophrenia : the QT interval issue in context. Taylor D CNS Drugs; 2003; 17(6):423-30. PubMed ID: 12697001 [TBL] [Abstract][Full Text] [Related]
14. Domperidone safety: a mini-review of the science of QT prolongation and clinical implications of recent global regulatory recommendations. Buffery PJ; Strother RM N Z Med J; 2015 Jun; 128(1416):66-74. PubMed ID: 26117678 [TBL] [Abstract][Full Text] [Related]
15. Drug-induced QT Interval Prolongation in the Intensive Care Unit. Etchegoyen CV; Keller GA; Mrad S; Cheng S; Di Girolamo G Curr Clin Pharmacol; 2017; 12(4):210-222. PubMed ID: 29473523 [TBL] [Abstract][Full Text] [Related]
16. Examination of baseline risk factors for QTc interval prolongation in patients prescribed intravenous haloperidol. Muzyk AJ; Rayfield A; Revollo JY; Heinz H; Gagliardi JP Drug Saf; 2012 Jul; 35(7):547-53. PubMed ID: 22702639 [TBL] [Abstract][Full Text] [Related]
17. A new biomarker--index of cardiac electrophysiological balance (iCEB)--plays an important role in drug-induced cardiac arrhythmias: beyond QT-prolongation and Torsades de Pointes (TdPs). Lu HR; Yan GX; Gallacher DJ J Pharmacol Toxicol Methods; 2013; 68(2):250-259. PubMed ID: 23337247 [TBL] [Abstract][Full Text] [Related]
18. Development of cardiac safety translational tools for QT prolongation and torsade de pointes. Valerio LG; Balakrishnan S; Fiszman ML; Kozeli D; Li M; Moghaddam S; Sadrieh N Expert Opin Drug Metab Toxicol; 2013 Jul; 9(7):801-15. PubMed ID: 23537164 [TBL] [Abstract][Full Text] [Related]